Pharmaceutical company Eli Lilly reported adjusted earnings per share of $8.55 for the first quarter, up significantly from $3.34 a year earlier.
Revenue came in at $19.8 billion, which was higher than analysts' estimates of $17.8 billion.
In conjunction with the report, management is raising its full-year forecast. Revenue for 2026 is now forecast to be in the range of $82-85 billion, compared to a previous estimate of $80-83 billion. The profit forecast is also being revised up.
